Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Rekvina Laboratories Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Rekvina Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Rekvina Laborato has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    8 Apr 2025, 2:40PM As of March 2025, 41.30% is owned by Indian Promoters and 58.70% by Public. <p align=justify> Top three Promoters holding highest number of shares of
  • Rekvina Laborato - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Apr 2025, 5:01PM Certificate Under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Key fundamentals

Evaluate the intrinsic value of Rekvina Laboratories Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets -0.0032 0.0131 0.0139 0.0928 0.157
Liabilities -0.0032 0.0131 0.0139 0.0928 0.157
Equity 3.014 3.014 3.014 3.014 3.014
Gross Profit -0.0164 -0.004 -0.0754 -0.0641 -0.1473
Net Profit -0.0164 -0.0007 -0.0788 -0.0642 0.0024
Cash From Operating Activities -0.0002 0.0099 -0.0399 -0.0088 -0.0123
NPM(%) 0 0 0 0 0
Revenue 0 0 0 0 0
Expenses 0.0164 0.004 0.0754 0.0641 0.1473
ROE(%) 512.5 23.28 2465.03 2006.25 -75

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Rekvina Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 824.20 -1.99 11.65 2.57 1321.50 1.39
Lotus Eye Hospital and Institute Ltd 80.41 -0.74 338.42 9.36 14.01 0.62
Bharat Immunological and Biologicals Corporation Ltd 23.00 -1.41 0.00 19.43 -39.50 0.00
Astec Lifesciences Ltd 681.00 -1.58 0.00 8.82 -687.11 0.00

Company Info

The Indian pharmaceutical industry is at the center stage in the global pharmaceutical arena and Rekvina is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of twenty crore INR. It is with the unwavering 'dedication' and the 'Will to Win ' of Team Rekvina across India that the Company have traversed this journey so far. The Company is so committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs & confident that our efforts would see the Company grow from strength to strength in the global space in the years to come. Whilst company continue to enhance the momentum of products, also accelerating drug discovery program through collaborations and alliances. As Company move ahead & determined to capitalize on the new opportunities based on our strong fundamentals of innovation, entrepreneurship and aggressive marketing. Still the Company remain committed to actively pursue strategy of growth through organic and inorganic means. Today, Company is well prepared to be amongst the top 100 pharmaceutical companies of India and attain a size of 100 crore INR by 2020. As It stepped into the next phase, driven by our ambition, willing to invest in the growth of our people and business, marching towards the new horizon of global leadership. Milestone of the Company  This company has introduced the concept of Dispersible Kid Tablets for Pediatric patients. Company's unique formulations include Prestigious product "REKFA", (Essential Fatty Acid - in Capsule, Cream & Pediatric Drop). Enthused by the market response, the group introduced many more specialised quality products for Human Health Care. It has introduced highly specialized products for Gynecological specialty and finally introduced prestigious product REKSEAL (Enbucrilate - n-Butylcyanoacrylate), the Tissue Adhesive which has further added a feather of success to the cap and lead to the introduction of still more specialised products. Vision Rekvina To emerge as a global Pharma player. To enter the advanced markets of the world with a sustained presence over the long-term. Planning proactively to introduce the right products at the right time with the support of WHO-GMP and other quality certifications. Introducing products in the gynecological disorders and surgical therapeutic segments. Entering advanced markets with New Chemical Entities (NCE). Maintaining the highest standards of current Good Manufacturing Practices (cGMP / Revised Schedule-M). Delivering customer value through a high quality of technical support, analytical data, technical documentation and regulatory compliance. Generating a cost advantage for its customers and the company through process innovation of raw material efficiency, innovative R&D and engineering. Making operations safe and reliable by minimizing waste, implementing effective waste treatment and protecting the environment. Mission Rekvina While committing to an on-going improvement in performance revolving around effective customer management, Company maintains: The highest levels of integrity in business conduct, A strong sense of public responsibility. To promote and provide an open and participative work environment with growth opportunities for all employees.  2014 -Rekvina Laboratories has splits its face value from Rs 10/- to 5/-

The Indian pharmaceutical industry is at the center stage in the global pharmaceutical arena and Rekvina is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of twenty crore INR. It is with the unwavering 'dedication' and the 'Will to Win ' of Team Rekvina across India that the Company have traversed this journey so far. The Company is so committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs & confident that our efforts would see the Company grow from strength to strength in the global space in the years to come. Whilst company continue to enhance the momentum of products, also accelerating drug discovery program through collaborations and alliances. As Company move ahead & determined to capitalize on the new opportunities based on our strong fundamentals of innovation, entrepreneurship and aggressive marketing. Still the Company remain committed to actively pursue strategy of growth through organic and inorganic means. Today, Company is well prepared to be amongst the top 100 pharmaceutical companies of India and attain a size of 100 crore INR by 2020. As It stepped into the next phase, driven by our ambition, willing to invest in the growth of our people and business, marching towards the new horizon of global leadership. Milestone of the Company  This company has introduced the concept of Dispersible Kid Tablets for Pediatric patients. Company's unique formulations include Prestigious product "REKFA", (Essential Fatty Acid - in Capsule, Cream & Pediatric Drop). Enthused by the market response, the group introduced many more specialised quality products for Human Health Care. It has introduced highly specialized products for Gynecological specialty and finally introduced prestigious product REKSEAL (Enbucrilate - n-Butylcyanoacrylate), the Tissue Adhesive which has further added a feather of success to the cap and lead to the introduction of still more specialised products. Vision Rekvina To emerge as a global Pharma player. To enter the advanced markets of the world with a sustained presence over the long-term. Planning proactively to introduce the right products at the right time with the support of WHO-GMP and other quality certifications. Introducing products in the gynecological disorders and surgical therapeutic segments. Entering advanced markets with New Chemical Entities (NCE). Maintaining the highest standards of current Good Manufacturing Practices (cGMP / Revised Schedule-M). Delivering customer value through a high quality of technical support, analytical data, technical documentation and regulatory compliance. Generating a cost advantage for its customers and the company through process innovation of raw material efficiency, innovative R&D and engineering. Making operations safe and reliable by minimizing waste, implementing effective waste treatment and protecting the environment. Mission Rekvina While committing to an on-going improvement in performance revolving around effective customer management, Company maintains: The highest levels of integrity in business conduct, A strong sense of public responsibility. To promote and provide an open and participative work environment with growth opportunities for all employees.  2014 -Rekvina Laboratories has splits its face value from Rs 10/- to 5/-

Read More

Parent Organisation

Rekvina Laboratories Ltd.

Founded

01/11/1988

Managing Director

Mr.Amit Mukesh Shah

NSE Symbol

FAQ

The current price of Rekvina Laboratories Ltd is

The 52-week high for Rekvina Laboratories Ltd is

The market capitalization of Rekvina Laboratories Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Rekvina Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Rekvina Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Rekvina Laboratories Ltd shares.

The CEO of Rekvina Laboratories Ltd is Mr.Amit Mukesh Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT